Rare diseases
Investigational molecules
Locations
346 conditions with trials, the busiest first
960 trials across Europe, recruiting first
Study of Capivasertib and Fulvestrant for Patients with Advanced or Metastatic HR+/HER2- Breast Cancer
BelgiumStudy on Elinzanetant for Treating Hot Flashes in Women with or at High Risk for Hormone-Receptor Positive Breast Cancer
AustriaStudy on Adding Apalutamide to Radiotherapy and LHRH Agonist for High-Risk Patients with Hormone-Sensitive Prostate Cancer
AustriaStudy of Palbociclib as an Alternative to Chemotherapy for Older Patients with High-Risk Early Breast Cancer
BelgiumStudy of pembrolizumab and vorinostat combination therapy in patients with recurrent or metastatic squamous cell carcinoma of head and neck, cervix, anus, and genital areas
FranceStudy Comparing Abemaciclib and Fulvestrant with Placebo and Fulvestrant for Patients with Advanced or Metastatic Breast Cancer After Previous Treatment
BelgiumStudy on the Safety and Effectiveness of Vepdegestrant and Samuraciclib for Adults with ER+ Advanced or Metastatic Breast Cancer
BelgiumStudy on MK-2870 for Patients with Endometrial Cancer After Platinum and Immunotherapy Treatment
AustriaStudy on the Safety and Effects of AZD5305 with Hormonal Agents for Patients with Metastatic Prostate Cancer
ItalyStudy on Trastuzumab Emtansine, Pertuzumab, and Atezolizumab for Patients with HER2-Positive Metastatic Cancer Who Benefited from Previous Treatment
BelgiumStudy of Apalutamide and Androgen Deprivation Therapy for Patients with Metastatic Hormone-sensitive Prostate Cancer
CzechiaStudy on the Safety of AZD8421 Alone or with Drug Combination for Patients with Advanced Breast Cancer and High-Grade Ovarian Cancer
SpainThe therapies tested most often in Reproductive system and breast disorders trials.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
